research use only

Prednisone Glucocorticoid Receptor agonist

Name: Prednisone
Brand: Selleck Chemicals
SKU: S1622
Availability: InStock
Rating: 5 (7 reviews)

Cat.No.S1622

Prednisone is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.

Chemical Structure

Molecular Weight: 358.43

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.91%

99.91

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor ACE RAAS Opioid Receptor THR PGES Aromatase 5-alpha Reductase CCK receptor Mineralocorticoid Receptor GHSR SSTR TSH Receptor GNRH Receptor PGDS
Related Products	AL082D06 (20S)-Protopanaxatriol Corticosterone Glucocorticoid Receptor Antibody [D9N22] Cortodoxone

Chemical Information, Storage & Stability

Molecular Weight	358.43	Formula	C₂₁H₂₆O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	53-03-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Adasone,NSC-10023			Smiles	CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C

Solubility

In vitro
Batch:

DMSO : 71 mg/mL (198.08 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.600mg/ml (10.04mM)	Taking the 1 mL working solution as an example, add 50 μL of 72 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (5.58mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Glucocorticoid receptor ^[1]
In vitro	Prednisone blocks Peripheral blood lymphocytes (PBL) growth in the G1 phase of cell cycle and inhibits both IL-2 receptor (IL-2R) expression and IL-2 secretion in activated human peripheral blood T lymphocytes. This compound increases apoptosis in PHA-activated human PBL, and the apoptotic effect of this chemical is stronger on CD8(+) than on CD4(+) T lymphocytes. ^[1]
In vivo	Prednisone-treated rats show a significant delay of 20% in learning and memory retention in rats as compared with controls. ^[2] This compound results in reduced weight gain, unchanged alter uterine weight, lowered serum magnesium (Mg), unchange serum calcium (Ca), phosphate (P), 25-hydroxyvitamin D (25OHD), or 1,25-dihydroxyvitamin D [1,25(OH)2D], striking increased in calcified cartilage, reduced cross-sectional area and cortical area, unchange medullary area of the tibial diaphysis, lowered periosteal and endocortical bone formation and apposition rates, increased mean cancellous bone area and cancellous bone perimeter of the tibial metaphysis in both sham-operated and ovariectomized rats. ^[3] This chemical-treated rabbit shows a 30% reduction in percent stenosis, a 35% decrease in neointimal area, and a 66% decrement in neointimal thickness. ^[4] This treatment significantly reduces the level of TGF-beta1 and HYP in diaphragm from mdx mice to values similar to control mice, but results in a higher level of the HP cross-link compared with untreated mdx mice. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/8608650/ [2] https://pubmed.ncbi.nlm.nih.gov/12425433/ [3] https://pubmed.ncbi.nlm.nih.gov/7767843/ [4] https://pubmed.ncbi.nlm.nih.gov/17616304/ [5] https://pubmed.ncbi.nlm.nih.gov/11353432/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06337695	Not yet recruiting	Cancer\|Cancer Metastatic	University of Calgary	July 1 2024	Phase 2\|Phase 3
NCT06394063	Not yet recruiting	Systemic Lupus Erythematosus	RenJi Hospital	June 30 2024	Not Applicable
NCT06360068	Not yet recruiting	Systemic Lupus Erythematosus	Qiong Fu\|RenJi Hospital	May 6 2024	Phase 2
NCT06037811	Not yet recruiting	Inflammatory Arthritis\|Immune-related Adverse Event	Tom Appleton\|Canadian Research Group in Immuno-Oncology\|Western University\|Lawson Health Research Institute	April 2024	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):